Actinogen Medical Annual General Meeting & Presentation

30th November 2016, ASX Announcement

Progress with the development of Xanamem

Since addressing you at the AGM this time last year, Actinogen has made substantial progress towards the initiation of XanADu, our Phase II study of Xanamem in mild Alzheimer’s disease. While we did expect to have initiated patient’s recruitment onto the trial by now, as previously announced, ongoing interaction with the FDA in America has led to some changes in the trial design, that required harmonising the protocol globally. We are particularly pleased with the progress we have made in recent correspondence with the FDA and have every expectation we will receive FDA approval in the near future, and to be able to start dosing patients into the study early in the new year. The trial will take around 2 years to complete, so we can expect top-line results by early 2019.

To view the full announcement, please click on the button below.

To view the full Presentation, please click on the button below.